Hence, finding alternative oncogenic signaling pathways activated in the absence of AR is key to disclose new therapeutic avenues for advanced PCa, particularly in the context of RT resistance and treatment-induced NED. The gene discussed is AR; the disease is posterior cortical atrophy.